CAR T therapy in adult DLBCL patients in Slovenia : evaluation of predictive scores for outcomes and adverse events

Sršen, Lucija (avtor), Auersperger, Irena (avtor), Janžič, Larisa (avtor), Kopitar, Andreja Nataša (avtor), Reberšek, Katarina (avtor), Jezeršek Novaković, Barbara (avtor), Novak, Polona (avtor), Rener, Karla (avtor), Šlajpah, Klara (avtor), Ihan, Alojz (avtor), Zver, Samo (avtor), Sever, Matjaž (avtor)

CAR T cell therapy is a promising immunotherapy for hematologic malignancies, yet early prediction of outcomes and adverse events remains difficult, especially in small real-world cohorts. We retrospectively analyzed 14 adult patients with diffuse large B-cell lymphoma (DLBCL) treated with CAR T cells in Slovenia, assessing IL-6 increase rates and established predictive metrics including EASIX-C, CAR-HEMATOTOX, and IBPS on Day −5 (pre-lymphodepletion) and Day 0 (infusion). Contrary to our expectation, an inverse correlation was observed between the increase rate of IL-6 and the occurrence of severe cytopenias, indicating higher IL-6 increase rate leads to less severe cytopenias. The EASIX-C score showed higher predictive values when calculated on Day 0, contrary to the CAR-HEMATOTOX score, whose higher predictive values were observed on Day −5. The IBPS predictive values showed mixed results when comparing Day −5 to Day 0. We observed 50% response rate and 29% remission rate. The results highlight the utility of predictive scores, with unexpected findings on IL-6 suggesting further study is necessary.

• Jezik: Angleški jezik
• Ključne besede: CAR T cell therapy, hematologic malignancies, diffuse large B-cell lymphoma, predictive scores, adverse events, therapeutic outcomes
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: MF - Medicinska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2026
• Št. strani: 12 str.
• Številčenje: Vol. 22, no. 1, art. 2620889
• PID: 20.500.12556/RUL-181494
• UDK: 616.1
• ISSN pri članku: 2164-5515
• DOI: 10.1080/21645515.2026.2620889
• COBISS.SI-ID: 267251459
• Datum objave v RUL: 09.04.2026

Gradivo je del revije

• Naslov: Human vaccines & immunotherapeutics
• Skrajšan naslov: Hum. vaccin. immunother.
• Založnik: Taylor & Francis
• ISSN: 2164-5515
• COBISS.SI-ID: 4534392

Licence

• Licenca: CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by-nc/4.0/deed.sl
• Opis: Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: celično zdravljenje CAR T, hematološke maligne bolezni, difuzni velikocelični limfom, neželeni učinki